341 related articles for article (PubMed ID: 1488568)
21. Efficacy and safety of ipratropium bromide/albuterol delivered via Respimat inhaler versus MDI.
Zuwallack R; De Salvo MC; Kaelin T; Bateman ED; Park CS; Abrahams R; Fakih F; Sachs P; Pudi K; Zhao Y; Wood CC;
Respir Med; 2010 Aug; 104(8):1179-88. PubMed ID: 20172704
[TBL] [Abstract][Full Text] [Related]
22. A comparison of the effects of anticholinergic and beta 2-agonist and combination therapy on respiratory impedance in COPD.
Wesseling G; Mostert R; Wouters EF
Chest; 1992 Jan; 101(1):166-73. PubMed ID: 1530836
[TBL] [Abstract][Full Text] [Related]
23. Delivery of fenoterol via Respimat, a novel 'soft mist' inhaler. a randomised, double-blind (within device), placebo-controlled, cross-over, dose-ranging study in asthmatic patients.
van Noord JA; Smeets JJ; Creemers JP; Greefhorst LP; Dewberry H; Cornelissen PJ
Respiration; 2000; 67(6):672-8. PubMed ID: 11124651
[TBL] [Abstract][Full Text] [Related]
24. The effects of inhaled ipratropium bromide, fenoterol and their combination in COPD patients.
Charoenpan P; Kiatboonsri S; Uswanopakhun P; Vongvivat K; Sulaimanee P
J Med Assoc Thai; 1990 Feb; 73(2):91-5. PubMed ID: 2141057
[TBL] [Abstract][Full Text] [Related]
25. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study Group.
Chest; 1994 May; 105(5):1411-9. PubMed ID: 8181328
[TBL] [Abstract][Full Text] [Related]
26. Bronchodilating effect of combined therapy with ipratropium bromide and ondansetron in patients with COPD.
Pauwels R; Joos GF; Fogarty C; Faiferman I; Hirschberg S; Vessey R; Wouters EF
Pulm Pharmacol Ther; 2008; 21(2):385-92. PubMed ID: 18023600
[TBL] [Abstract][Full Text] [Related]
27. Addition of anticholinergic solution prolongs bronchodilator effect of beta 2 agonists in patients with chronic obstructive pulmonary disease.
Levin DC; Little KS; Laughlin KR; Galbraith JM; Gustman PM; Murphy D; Kram JA; Hardie G; Reuter C; Ostransky D; McFarland K; Petty TL; Silvers W; Rennard SI; Mueller M; Repsher LH; Zuwallack RL; Vale R
Am J Med; 1996 Jan; 100(1A):40S-48S. PubMed ID: 8610716
[TBL] [Abstract][Full Text] [Related]
28. For COPD a combination of ipratropium bromide and albuterol sulfate is more effective than albuterol base.
Campbell S
Arch Intern Med; 1999 Jan; 159(2):156-60. PubMed ID: 9927098
[TBL] [Abstract][Full Text] [Related]
29. The role of domiciliary nebulizers in managing patients with severe COPD.
Eiser N; Angus K; McHale S
Respir Med; 2001 Apr; 95(4):265-74. PubMed ID: 11316108
[TBL] [Abstract][Full Text] [Related]
30. Bronchodilator action of inhaled fenoterol and ipratropium in normal subjects: a teaching exercise for medical students.
Taylor RG; Maclagan J; Cook DG
Br J Clin Pharmacol; 1989 Dec; 28(6):709-13. PubMed ID: 2532922
[TBL] [Abstract][Full Text] [Related]
31. Comparison between fenoterol/ipratropium bromide combinations and salbutamol administered as nebulizer solution assessing dose-response and duration of action.
McIntosh D
Respiration; 1986; 50 Suppl 2():310-2. PubMed ID: 2951827
[TBL] [Abstract][Full Text] [Related]
32. Ipratropium bromide and fenoterol by aerosolized solution.
Jenkins CR; Chow CM; Fisher BL; Marlin GE
Br J Clin Pharmacol; 1982 Jul; 14(1):113-5. PubMed ID: 6213250
[TBL] [Abstract][Full Text] [Related]
33. Preliminary data from phase II studies with Respimat, a propellant-free soft mist inhaler.
Pavia D; Moonen D
J Aerosol Med; 1999; 12 Suppl 1():S33-9. PubMed ID: 10623340
[TBL] [Abstract][Full Text] [Related]
34. Effects of inhaled oxitropium and fenoterol, alone and in combination, in chronic airflow obstruction.
Frith PA; Jenner B; Atkinson J
Respiration; 1986; 50 Suppl 2():294-7. PubMed ID: 3563116
[TBL] [Abstract][Full Text] [Related]
35. A placebo-controlled comparison between the bronchodilatory effects of ipratropium bromide inhaled as a dry powder and by metered dose inhaler in chronic obstructive pulmonary disease.
Gimeno F; van Veenen R; Berg WC; Steenhuis EJ
Ann Allergy; 1988 Nov; 61(5):341-3. PubMed ID: 2973269
[TBL] [Abstract][Full Text] [Related]
36. Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease.
van Noord JA; Smeets JJ; Custers FL; Korducki L; Cornelissen PJ
Eur Respir J; 2002 Apr; 19(4):639-44. PubMed ID: 11998992
[TBL] [Abstract][Full Text] [Related]
37. Fenoterol hydrobromide delivered via HFA-MDI or CFC-MDI in patients with asthma: a safety and efficacy comparison.
Goldberg J; Böhning W; Schmidt P; Freund E
Respir Med; 2000 Oct; 94(10):948-53. PubMed ID: 11059947
[TBL] [Abstract][Full Text] [Related]
38. Pharmacodynamic study of procaterol hydrochloride dry powder inhaler: evaluation of pharmacodynamic equivalence between procaterol hydrochloride dry powder inhaler and procaterol hydrochloride metered-dose inhaler in asthma patients in a randomized, double-dummy, double-blind crossover manner.
Kawai M; Sakai A; Takaori S; Hiura A; Sakata N; Nakashima M; Miyamoto T
Methods Find Exp Clin Pharmacol; 2005; 27(6):385-9. PubMed ID: 16179955
[TBL] [Abstract][Full Text] [Related]
39. Studies on the bronchodilator, tremorogenic, cardiovascular and hypokalaemic effects of fenoterol dry powder in asthma.
Bauer KG; Kaik B; Sertl K; Kaik GA
Br J Clin Pharmacol; 1993 Oct; 36(4):285-92. PubMed ID: 12959305
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trial.
Donohue JF; Wise R; Busse WW; Garfinkel S; Zubek VB; Ghafouri M; Manuel RC; Schlenker-Herceg R; Bleecker ER
BMC Pulm Med; 2016 Apr; 16(1):65. PubMed ID: 27130202
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
